Inhibitor Therapeutics (INTI) Common Equity (2012 - 2026)
Inhibitor Therapeutics' (INTI) quarterly Common Equity came in at -$2.0 million in Q1 2026, down 246.31% YoY from $1.4 million in Q1 2025, and down 53.13% on a QoQ basis from -$1.3 million in Q4 2025.
Inhibitor Therapeutics (INTI) Common Equity (2012 - 2026) Analysis & Trends
Inhibitor Therapeutics (INTI) has 15 years of Common Equity data on file, last reported at -$2.0 million in Q1 2026.
- Quarterly Common Equity fell 246.31% year-over-year to -$2.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$2.0 million (down 246.31% YoY) and the FY2025 annual result came in at -$1.3 million, down 165.08% from the prior year.
- Common Equity declined to -$2.0 million in Q1 2026, from -$1.3 million in the prior quarter.
- In the past five years, Common Equity ranged from a high of $8.3 million in Q4 2022 to a low of -$4.0 million in Q3 2022.
- A 5-year average of $2.1 million and a median of $2.0 million in 2024 frame the typical range for Common Equity.
- Annual changes were most pronounced in 2022 — Common Equity surged 329.13% — and 2026, when it tumbled 246.31%.
- Tracing INTI's Common Equity over 5 years: stood at $8.3 million in 2022, then plunged by 36.31% to $5.3 million in 2023, then plunged by 62.43% to $2.0 million in 2024, then tumbled by 165.08% to -$1.3 million in 2025, then tumbled by 53.13% to -$2.0 million in 2026.
- The last three Common Equity figures came in at -$2.0 million (Q1 2026), -$1.3 million (Q4 2025), and $3453.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 6.76 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 5.17 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 1.35 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 22.38 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 757.49 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 9.79 Bn |
| 10 | Inhibitor Therapeutics | 15.64 Mn | 15.64 Mn | - | -2.56 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1.98 Mn |
| Dec 31, 2025 | -1.29 Mn |
| Sep 30, 2025 | 3,453.00 |
| Jun 30, 2025 | 715,637.00 |
| Mar 31, 2025 | 1.35 Mn |
| Dec 31, 2024 | 1.99 Mn |
| Sep 30, 2024 | 3.41 Mn |
| Jun 30, 2024 | 4.14 Mn |
| Mar 31, 2024 | 4.64 Mn |
| Dec 31, 2023 | 5.28 Mn |
| Sep 30, 2023 | 6.45 Mn |
| Jun 30, 2023 | 7.11 Mn |
| Mar 31, 2023 | 7.76 Mn |
| Dec 31, 2022 | 8.30 Mn |
| Sep 30, 2022 | -4.02 Mn |
| Jun 30, 2022 | -3.90 Mn |
| Mar 31, 2022 | -3.77 Mn |
| Dec 31, 2021 | -3.62 Mn |
| Sep 30, 2021 | -3.54 Mn |
| Jun 30, 2021 | -3.51 Mn |